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Accumulation of both interstitial myofibroblasts and
excessive production of extracellular matrix proteins is a
common pathway contributing to chronic kidney disease.
In a number of tissues, activation of STAT3 (signal transducer
and activator of transcription 3) increases expression of
multiple profibrotic genes. Here, we examined the effect of a
STAT3 inhibitor, S3I-201, on activation of renal interstitial
fibroblasts and progression of renal fibrosis. Treatment of
cultured rat renal interstitial fibroblasts with S3I-201 inhibited
their activation, as evidenced by dose- and time-dependent
blockade of a-smooth muscle actin and fibronectin
expression. In a mouse model of renal interstitial fibrosis
induced by unilateral ureteral obstruction, STAT3 was
activated, and administration of S3I-201 attenuated both this
activation and extracellular matrix protein deposition
following injury. S3I-201 reduced infiltration of the injured
kidney by inflammatory cells and suppressed the injury-
induced expression of fibronectin, a-smooth muscle actin,
and collagen type-1 proteins, as well as the expression of
multiple cytokines. Furthermore, S3I-201 inhibited
proliferation and induced apoptosis preferentially in renal
interstitial fibroblasts of the obstructed kidney. Thus, our
results suggest that increased STAT3 activity mediates
activation of renal interstitial fibroblasts and the progression
of renal fibrosis. Inhibition of STAT3 signaling with S3I-201
may hold therapeutic potential for fibrotic kidney diseases.
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Renal tubulointerstitial fibrosis is the final common pathway
in end-stage renal disease and is characterized by aberrant
activation and growth of the renal fibroblasts.1,2 The
activation of interstitial fibroblasts to become a-smooth
muscle actin (a-SMA)-positive myofibroblasts is the key step
in the evolution of chronic kidney disease (CKD). Therefore,
targeting the signaling pathway(s) that mediate the activation
of myofibroblasts may be a way to attenuate the progression
of renal fibrosis.
Among the signaling pathways reported to be associated
with activation of renal interstitial fibroblasts,1,3 transforming
growth factor-b1 (TGF-b1) signaling has a major role in this
process.4–6 TGF-b1 induces its biological effects by interac-
tion with TGF-b receptor type-I (TbRI), type-II (TbRII), and
type-III (TbRIII).7,8 Upregulation of TGF-b1 and TGF-b
receptors has been observed in various forms of chronic renal
fibrotic diseases in animal models and in humans.4,9 In
addition, accumulation of inflammatory cells and expression
of some proinflammatory mediators such as tumor necrosis
factor-a (TNF-a), interleukin-1b (IL-1b), intercellular adhe-
sion molecule-1 (ICAM-1), and monocyte chemotactic
protein-1 (MCP-1) also contribute to the development of
renal fibrosis in human and animal models of CKD.3,10–12
Signal transducer and activator of transcription 3 (STAT3)
has been reported to induce expression of multiple genes,
including TGF-b1.13–15 STAT3 belongs to a family comprised
of seven members (STAT1–4, STAT5a, STAT5b, and STAT6)
and mediates various cellular functions, including cell
survival and proliferation.16,17 In response to numerous
growth factors and cytokines such as TGF-b1,18 platelet-
derived growth factor,19,20 and IL-6,21,22 STAT3 is activated
by tyrosine phosphorylation at tyrosine 705 through Janus
kinases. Phosphorylated STAT3 forms dimers and then
translocates to the nucleus, where it directly binds to the
DNA sequence and regulates expression of target genes.13–15
Increased STAT3 activation by phosphorylation at tyrosine
705 has been observed in interstitial fibroblasts of the fibrotic
kidney induced by unilateral ureteral obstruction (UUO).23
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However, the functional role of STAT3 in activation of renal
fibroblasts and development of renal interstitial fibrosis has
not been examined in vivo.
Recently, S3I-201, a novel selective inhibitor of STAT3, has
been synthesized and used to treat tumors. S3I-201
preferentially inhibits STAT3 DNA-binding activity and
diminishes STAT3 tyrosine phosphorylation.24 In this study,
we evaluated the therapeutic effect of S3I-201 on the
activation of renal interstitial fibroblasts in vitro using rat
NRK-49F cells, a rat renal interstitial fibroblast line, and the
progression of renal fibrosis in a murine model of the fibrotic
kidney induced by UUO injury. Furthermore, we investigated
the effect of S3I-201 on the expression of some cytokines
associated with the development of progressive renal fibrosis.
RESULTS
S3I-201 decreases expression of a-SMA and fibronectin in
cultured renal interstitial fibroblasts
Myofibroblasts are active fibroblasts characterized by expres-
sion of a-SMA and fibronectin.3 To understand whether
STAT3 activation is required for activation of renal interstitial
fibroblasts, we examined the effect of S3I-201 on expression
of a-SMA and fibronectin in NRK-49F cells. As shown in
Figure 1a–d, both a-SMA and fibronectin were highly
expressed in NRK-49F cells, indicating that the cultured
renal interstitial fibroblasts are phenotypically myofibro-
blasts. Incubation of cells with S3I-201 dramatically
decreased the expression of a-SMA and fibronectin in a
dose- and time-dependent manner, suggesting that STAT3
mediates activation of renal interstitial fibroblasts.
The STATs are activated by tyrosine phosphorylation.25,26
p-STAT3 and p-STAT5, but not p-STAT1, were constitutively
expressed in cultured NRK-49F cells. Treatment with S3I-201
dose-dependently inhibited the expression of p-STAT3 with a
complete inhibition at 100 mM (Figure 1e and f). S3I-201
treatment did not affect STAT5 phosphorylation, but
increased expression of p-STAT1 in a dose-dependent
manner (Supplementary Figure S1). These data suggest that
S3I-201 is a highly selective inhibitor of STAT3 and is able to
block expression of the constitutively activated STAT3 in
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Figure 1 | Effect of S3I-201 on the expression of a-smooth muscle actin (a-SMA) and fibronectin. Cultured NRK-49F cells were treated
with S3I-201 for the indicated concentrations for 24 h (a) or 3 h (e), or exposed to 50mM S3I-201 for the indicated time period (c). Cell lysates
were subjected to immunoblot analysis using antibodies to a-SMA, fibronectin, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Representative immunoblots from three or more experiments are shown. Expression levels of the indicated proteins were quantified
by densitometry and normalized with GAPDH (b, d). Activated signal transducer and activator of transcription 3 (STAT3) was depicted with
p-STAT3/STAT3 ratio (f). Data are means± s.e.m. Significant P-values reflecting differences are indicated over the bars (*Po0.05; **Po0.01).
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renal interstitial fibroblasts. Furthermore, STAT3 may
negatively regulate STAT1 activation. As recent studies have
documented that both STAT1 and STAT5 have a role in
suppression of tissue fibrosis, in contrast to STAT3,27,28
increased expression of p-STAT1 and preservation of
p-STAT5 may be beneficial to the alleviation of renal fibrosis
after injury.
Downregulation of STAT3 by siRNA inhibits expression of
a-SMA and fibronectin in cultured renal interstitial
fibroblasts
To confirm the role of STAT3 in mediating a-SMA and
fibronectin expression in NRK-49F cells, small interfering
RNA (siRNA) targeting STAT3 was transfected to NRK-49F
cells by electroporation to downregulate STAT3, and expres-
sion of a-SMA and fibronectin was examined by immunoblot
analysis. Figure 2 shows that knockdown of STAT3 decreased
expression of a-SMA and fibronectin in NRK-49F cells
(Figure 2). These data support our conclusions that STAT3 is
critically involved in activation of cultured renal interstitial
fibroblasts.
STAT3 phosphorylation and expression in the obstructive
kidney
On the basis of the above observation, we hypothesized that
STAT3 has an essential role in mediating the development of
renal interstitial fibrosis in vivo. To test this hypothesis, we first
examined the activation and expression of STAT3 in
obstructive nephropathy, a model of predominantly tubuloin-
terstitial lesions that are characterized by accumulation and
activation of myofibroblasts.29 As shown in Figure 3a and b,
the basal level of STAT3, but not p-STAT3, was observed in
sham-operated kidneys. UUO injury caused STAT3 tyrosine
phosphorylation, which evolves in two waves: the first on day
1 and the second on day 7. STAT3 tyrosine phosphorylation
then remained elevated until at least 14 days after UUO injury.
Whereas p-STAT3 expression declined on day 3 after UUO
injury, total STAT3 expression was still upregulated at this
point. On day 7, expression of STAT3 reached its maximum
and kept this level until at least 14 days after UUO injury.
Previous work indicates that p-STAT3 is preferentially
expressed in myofibroblasts in rat kidneys subjected to UUO
injury.23 To determine whether this is also the case in the
mouse model of UUO, we performed double immunostain-
ing for a-SMA and p-STAT3 in kidney tissue after UUO
injury. Most of the cells localized to the interstitium stained
for both a-SMA and p-STAT3, and a small number of cells
stained only for a-SMA. Cells stained only for p-STAT3 were
observed only occasionally (Figure 3d and e). Therefore,
these data illustrate that STAT3 is preferentially activated in
renal interstitial fibroblasts after UUO injury.
S3I-201 inhibits STAT3 phosphorylation in the obstructive
kidney
As an initial step toward understanding the role of STAT3 in
renal fibrosis, we examined the effect of S3I-201 on the
expression of p-STAT3 in the kidney following obstructive
injury. Contralateral kidneys were used as controls. As shown
in Figure 4, daily administration of S3I-201 at 10mg/kg
largely suppressed STAT3 phosphorylation on day 7 and a
small inhibition on day 14 after UUO (Supplementary Figure
S3). Total STAT3 expression was not affected by this
treatment at both time points. These data indicate that
UUO injury induces both activation of STAT3 and
upregulation of STAT3 protein, and that S3I-201 is an
effective inhibitor of STAT3 activation without changing
STAT3 protein levels. Furthermore, S3I-201 is more effective
in inhibiting STAT3 activation in the early phase of
obstructive nephropathy. The reason for the different effect
of this inhibitor at the early and later time points is currently
unknown, but may be associated with change in the signal
responsible for STAT3 activation due to increased injury over
time. Further studies are needed to address the mechanism
that regulates STAT3 activation at different phases.
S3I-201 attenuates deposition of ECM components
An increase in extracellular matrix (ECM) is the major
feature of renal fibrosis.4,30 To determine whether STAT3
activation is involved in the regulation of renal interstitial
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Figure 2 | Effect of signal transducer and activator of
transcription 3 (STAT3) small interfering RNA (siRNA) on the
expression of a-smooth muscle actin (a-SMA) and fibronectin.
Cultured NRK-49F cells were transfected with siRNA targeting
STAT3 or scrambled siRNA. At 48 h after transfection, cell lysates
were subjected to immunoblot analysis using antibodies to
STAT3, a-SMA, fibronectin, and a-tubulin. Representative
immunoblots from three or more experiments are shown (a).
Expression levels of the indicated proteins were quantified by
densitometry and normalized with a-tubulin (b). Data are means
± s.e.m. Significant P-values reflecting differences in the
expression of individual proteins as indicated between cells
treated with STAT3 siRNA and those treated with scrambled
siRNA (*Po0.05).
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ECM deposition after obstructive injury, we evaluated the
effect of S3I-201 on the expression of interstitial collagen
fibrils by Sirius red staining. An increase in Sirius red-positive
areas was observed within the tubulointerstitium after UUO
injury. S3I-201 treatment significantly reduced such areas
(Figure 5c and d). A semiquantitative analysis of Sirius red-
positive areas reveals a 9.5-fold increase in the obstructive
kidney compared with sham-operated kidneys. Treatment
with S3I-201 decreased the expression of ECM components
by B60% (Figure 5e).
S3I-201 inhibits expression of collagen type-1 and a-SMA, but
not b-catenin and snail after obstructive injury
To further elucidate the role of STAT3 in fibroblast activation
and production of a particular ECM protein, we examined
the effect of S3I-201 on the expression of collagen type-1 and
a-SMA, the hallmark of fibroblast activation, after UUO
injury.4 As indicated in Figure 6a–c, basal levels of a-SMA
and abundant collagen type-1 were detected in the kidney
tissue of sham-operated mice. UUO injury resulted in a
marked increase in their expression. S3I-201 treatment
inhibited a-SMA expression and also decreased collagen
type-1 to the basal level in obstructive kidneys. Interestingly,
S3I-201 did not affect the basal levels of collagen type-1 and
a-SMA expression in control kidneys. In addition, we also
examined the effect of S3I-201 on the expression of collagen
type-1 at mRNA level and found that UUO injury
also resulted in increased expression of collagen type-1
(Figure 6d), whereas S3I-201 treatment attenuated this
response. In contrast to those observations, administration
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Figure 3 | Expression of phosphorylated signal transducer and activator of transcription 3 (p-STAT3) and STAT3 following unilateral
ureteral obstruction (UUO) injury. The left ureter was ligated. (a–c) At days 1, 3, 7, and 14, the kidneys were taken for analysis of
expression of p-STAT3, STAT3, and tubulin. Representative immunoblots from three or more experiments are shown. After urethra ligation,
kidneys were taken at 1, 3, 7, and 14 days. Expression levels of p-STAT3 and STAT3 (*Po0.05) (b and c) were quantified by densitometry
and normalized with tubulin. Kidney tissue collected at day 7 was used for costaining with antibodies to a-smooth muscle actin (a-SMA) and
p-STAT3. Interstitial cells with positive staining for both a-SMA and p-STAT3, or a-SMA, or p-STAT3 alone were counted in 25 high-power
fields and expressed as means ± s.e.m. (d).
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of S3I-201 did not affect expression of b-catenin and snail
(Supplementary Figure S4). Therefore, increased collagen
type-1 and a-SMA after UUO injury, rather than their basal
levels, are regulated by STAT3. Furthermore, STAT3 does not
have a role in regulation of b-catenin and snail, two trans-
criptional regulators involved in the epithelial–mesenchymal
transition.31,32
We further examined the effect of S3I-201 on activation
of renal interstitial fibroblasts on day 14 after UUO injury.
S3I-201 at 10mg/kg also decreased a-SMA and collagen
type-1 expression at that time, but not to significant levels
(Supplementary Figure S3). Reduced effects of S3I-201 on
activation of renal interstitial fibroblasts at the later time
point is currently unclear and needs further investigations.
S3I-201 inhibits expression of fibronectin after obstructive
injury
To determine whether S3I-201 administration inhibits other
ECM proteins, we assessed the effect of S3I-201 on
fibronectin expression by immunostaining and immunoblot
analysis. Fibronectin staining showed increased expression of
fibronectin after UUO injury. S3I-201 administration dec-
reased its expression (Figure 7a–d). Similar results were also
obtained by immunoblot analysis of kidney tissue lysates
(Figure 7e). Densitometry analysis of immunoblot results
showed a significant increase in the expression of fibronectin
in the kidneys of mice following UUO, compared with
control sham-operated mice. In contrast, fibronectin expres-
sion was blocked in mice treated with S3I-201 (Figure 7f).
These data, taken together with the inhibitory effect of S3I-
201 on collagen type-1 expression, suggest that STAT3 is
critically involved in the production of ECM proteins after
UUO injury.
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Figure 4 | Effect of S3I-201 on UUO-induced signal transducer and activator of transcription 3 (STAT3) activation. Kidney tissue
lysates were subjected to immunoblot analysis with specific antibodies against p-STAT3 (Tyr705), STAT3, or glyceraldehyde 3-phosphate
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Figure 5 | Effect of S3I-201 on the deposition of extracellular
matrix (ECM) in obstructive kidneys. Photomicrographs
illustrating Sirius red staining of kidney tissue after various
treatments: (a) sham with vehicle; (b) sham with S3I-201; (c) UUO
with vehicle; and (d) UUO with S3I-201. The graph shows the
percentage of Sirius red-positive tubulointerstitial area (red)
relative to the whole area from 10 random cortical fields ( 200)
(means± s.e.m.) (e). Significant P-values reflecting differences are
indicated over the bars (*Po0.05; **Po0.01). Note the ECM
deposition areas (arrows).
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S3I-201 decreases TGF-b1 and TbRII upregulation induced by
obstructive injury
As increased expression of TGF-b1 and/or TGF-b receptors is
found in almost all forms of kidney diseases with interstitial
fibrosis,4 we examined the effects of S3I-201 on the
expression of TGF-b1 and three TGF-b receptors (type-I,
type-II, and type-III) in obstructive kidneys using real-time
PCR. Expression of TGF-b1 and TbRII was significantly
increased in mice after obstructive injury, and administration
of S3I-201 reduced their levels (Figure 8a and c). In contrast,
expression levels of TbRI and TbRIII were not changed after
UUO injury compared with control groups (Figure 8b and
d). Interestingly, S3I-201 still reduced the basal level of
TbRIII, whereas TbRI expression at the basal level was not
affected by this treatment. Similarly, S3I-201 significantly
decreased expression of TGF-b1, TbRII, and TbRIII,
but not of TbRI in cultured renal interstitial fibroblasts
(Supplementary Figure S2). In addition, we examined
expression levels of TGF-b1 protein using the enzyme-linked
immunosorbent assay (ELISA) assay and showed that S3I-
201 also decreased expression of TGF-b1 protein in
obstructive kidneys (Figure 8e). These data indicate that
STAT3 mediates expression of both TGF-b1 and its receptor,
TbRII, in the obstructive kidney.
Effect of S3I-201 on leukocyte infiltration and expression of
proinflammatory cytokines after obstructive injury
We also examined the effect of S3I-201 on leukocyte
infiltration and expression of multiple proinflammatory
cytokines, including TNF-a, IL-1b, MCP-1, and ICAM-1.
Staining of kidney sections with naphthol-AS-D-chloroace-
tate esterase showed prominent interstitial infiltration of
neutrophils and monocytes after obstructive injury. S3I-201
treatment reduced leukocyte infiltration to basal levels
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Figure 6 | Effect of S3I-201 on UUO-induced a-smooth muscle actin (a-SMA) and collagen type-I (collagen I) expression. (a) Kidney
tissue lysates were subjected to immunoblot analysis with specific antibodies against a-SMA, collagen I, or a-tubulin. Expression levels
of a-SMA (b) and collagen I (c) were quantified by densitometry and normalized with a-tubulin. Data are means ± s.e.m. (n¼ 6).
(d) mRNA was extracted from kidney tissues of sham-operated or obstructed kidneys with/without S3I-201 administration and subjected
to quantitative real-time reverse transcriptase PCR, as described in ‘Materials and Methods’. mRNA expression levels of collagen I were
indicated as fold induction over control (sham-operated mice treated with vehicle). Significant P-values reflecting differences are indicated
over the bars (*Po0.05; **Po0.01).
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(Figure 9). The expression levels of TNF-a, IL-1b, ICAM-1,
and MCP-1 were also increased in obstructive kidneys. S3I-
201 treatment reduced expression of TNF-a, IL-1b, and
ICAM-1 mRNA, but did not affect UUO injury-induced
MCP-1 mRNA expression (Figure 10a–d). To verify these
observations, we examined the effect of S3I-201 on the
expression of TNF-a and IL-1b proteins using the ELISA
assay. S3I-201 also significantly suppressed their expression at
the protein levels (Figure 10e and f). These data suggest that
STAT3 activity contributes to leukocyte infiltration and is
selectively involved in the production of proinflammatory
cytokines in UUO-induced renal fibrosis.
Effect of S3I-201 on proliferation and apoptosis of renal
interstitial fibroblasts after obstructive injury
We further examined the effect of S3I-201 on apoptosis and
proliferation of renal interstitial fibroblasts after UUO injury
using the terminal deoxynucleotidyl transferase biotin-dUTP
nick end labeling (TUNEL) assay and by evaluating cells for
phosphohistone (Ser-10) positivity, respectively. Phosphor-
ylation of histone H3 at this site specifically mark cells
undergoing mitosis.33,34 As shown in Supplementary Figures
S5 and S6, animals with UUO injury displayed a greater
number of TUNEL-positive and p-histone H3-positive cells,
predominantly in the renal interstitium. S3I-201 treatment
resulted in increased apoptosis of interstitial cells and
decreased their proliferation. S3I-201 administration did
not induce apoptosis of renal tubular cells (Supplementary
Figure S5b). These data illustrate that UUO injury-induced
STAT3 activation contributes to survival and proliferation of
interstitial cells, most probably renal interstitial fibroblasts.
DISCUSSION
Using S3I-201, a selective inhibitor of STAT3,24 we provided
evidence that STAT3 activity is necessary for the activation
and proliferation of renal interstitial fibroblasts and the
destruction of the kidney. We have shown that S3I-201
treatment inhibits the expression of a-SMA and interstitial
ECM proteins, decreases proliferation of renal interstitial
fibroblasts, attenuates progression of renal fibrosis, and
suppresses infiltration of leukocytes and expression of
multiple inflammatory cytokines in obstructive nephropathy.
In this study, we observed that UUO injury induces STAT3
phosphorylation at tyrosine 705 in the fibrotic mouse kidney,
as early as day 1, reaching a maximum level at day 7, and
remaining elevated for 14 days after UUO injury. Further
immunohistochemical analysis localized p-STAT3 in most
tubulointerstitial cells expressing a-SMA (Figure 3). These
observations correlate with the findings of Kuratsune et al.,23
indicating that p-STAT3 preferentially colocalizes with a-
SMA in the tubulointerstitium in the rat kidney. The marked
and persistent increase in activated STAT3 in the interstitial
cells of fibrotic kidney suggests the importance of STAT3 in
mediating activation of renal interstitial fibroblasts and
progression of renal fibrosis following UUO injury. Indeed,
inactivation of STAT3 by S3I-201 significantly attenuated the
pathogenesis of renal fibrosis as described above. Further-
more, inhibition of STAT3 with either S3I-201 or its specific
siRNA blocked the expression of a-SMA and fibronectin in
cultured renal interstitial fibroblasts (Figures 1a–d and 2a–b).
The STAT3 activation can be induced by multiple growth
factors and cytokines such as TGF-b1,18 platelet-derived
growth factor,19,20 and IL-6,21,22 that contribute to the
development of renal fibrosis,35,36 and increased expression
of activated STAT3 was detected in several kidney diseases
associated with progressive fibrosis, including glomerulone-
phritis and diabetic nephropathy.37,38 Thus, we suggest that
STAT3 may act as a common mediator in chronic renal
damage. Consistent with our observations on the profibrotic
role of STAT3 in the kidney, hyperactivated STAT3 has also
been reported to be associated with chemically induced liver
fibrosis15 and scar formation after spinal cord injury.39
Inhibition of STAT3 activation may elicit an antifibrotic
effect by multiple mechanisms. As TGF-b1 signaling has a
central role in a variety of fibrogenic processes such as
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Figure 7 | Effect of S3I-201 on UUO-induced fibronectin
expression. Photomicrographs illustrate fibronectin (green color)
with immunofluorescent staining after various treatments:
(a) sham with vehicle; (b) sham with S3I-201; (c) UUO with vehicle;
and (d) UUO with S3I-201. Kidney tissue lysates were subjected to
immunoblot analysis with specific antibodies against fibronectin
(e). Expression levels of fibronectin in different groups were
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±s.e.m. (n¼ 6). Significant P-values reflecting differences are
indicated over the bars (*Po0.05; **Po0.01).
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fibroblast activation, and STAT3 is a known transcription
factor,4–6,16 we examined the effect of S3I-201 on the
expression of TGF-b1 and TGF-b receptors in the kidney
after UUO. Our results clearly indicated that expression levels
of TGF-b1 and TbRII mRNA were upregulated in the
obstructed kidney, and S3I-201 treatment suppressed their
expression (Figure 8a and c). Furthermore, treatment with
S3I-201 also suppressed the expression of TGF-b1 protein in
the obstructed kidney (Figure 8e). Thus, we suggest that S3I-
201-elicited inhibition of myofibroblast activation is likely
mediated by antagonizing TGF-b1 signaling through sup-
pression of TGF-b1 and TbRII expression. Two potential
STAT3-binding sites have been reported to exist in the
promoter region of TGF-b1 and STAT3 activates promoter
activity in vitro, suggesting that STAT3 may directly regulate
TGF-b1 gene expression.15
Progression of renal fibrosis is closely associated with the
inflammatory response. We observed that administration of
S3I-201 inhibited infiltration of neutrophils and monocytes
and suppressed the expression of TNF-a, IL-1b, and ICAM-1,
but not MCP-1, in the obstructed kidney. These results
suggest that inhibition of inflammatory responses may be
another mechanism by which S3I-201 attenuates renal
fibrosis. As MCP-1 is a chemokine for monocytes, we also
suggest that STAT3 may induce monocyte infiltration into
sites of injury in the kidney through a mechanism that is not
involved in MCP-1 expression. In addition to MCP-1, other
chemokines such as RANTES, monocyte inflammatory
protein-1a, and macrophage inflammatory protein are also
associated with the progression of renal fibrosis.40–42 It will be
interesting to examine whether STAT3 diminishes monocyte
infiltration by reducing expression of those chemokines.
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Figure 8 | Effect of S3I-201 on mRNA and protein expression of transforming growth factor-b1 (TGF-b1) and mRNA expression of
TGF-b receptors. mRNA was extracted from kidney tissues of sham-operated or obstructed kidneys with/without S3I-201 administration
and subjected to quantitative real-time reverse transcriptase PCR, as described in ‘Materials and Methods’. mRNA expression levels of
TGF-b1 (a), TGF-b receptor type-I (TbR I) (b), type-II (TbR II) (c) and type-III (TbR III) (d) were indicated as fold induction over control
(sham-operated mice treated with vehicle). Protein expression levels of TGF-b1 in each group were measured by the enzyme-linked
immunosorbent assay (ELISA) (e). Data are mean ± s.e.m. (n¼ 6). Significant P-values reflecting differences are indicated over the bars
(*Po0.05; **Po0.01).
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S3I-201 is a selective and potent inhibitor of constitutive
activation of STAT3 DNA-binding and STAT3-mediated gene
expression.24 Unlike other commonly used STAT3 inhibitors
such as AG490, which act on Janus kinases, the upstream
activators of STAT3, and other STAT isoforms,43–45 S3I-201
inhibits STAT3–STAT3 complex formation and STAT3 DNA-
binding and transcriptional activities in cells that contain
constitutively activated STAT3.24 By binding to STAT3, S3I-
201 may also prevent STAT3 protein from binding to the
pTyr motifs of the receptor tyrosine kinases and subsequently
block de novo phosphorylation by tyrosine kinases.24 These
properties are very important for the treatment of renal
fibrosis, as recent studies using knockout mice showed that in
contrast to STAT3, STAT1 and STAT5 have a role in
abrogating liver and lung fibrosis after injury.27,28 Our results
showed that S3I-201, at the concentration that blocked
STAT3 phosphorylation, increased expression of p-STAT1 but
did not affect that of p-STAT5 in NRK-49F cells (Supple-
mentary Figure S1), suggesting that the resultant increased
expression of p-STAT1 and preservation of p-STAT5 in renal
interstitial fibroblasts after STAT3 inhibition may also be
important for attenuating the progression of tissue fibrosis.
The expanded population of fibroblasts in the diseased
kidney could result from an increase in proliferation and/or a
decrease in cell death.35,46 Our results showed that admin-
istration of S3I-201 inhibited proliferation and promoted
death in renal interstitial cells at day 7 after UUO injury
(Supplementary Figures S5 and S6). In view of the fact that
most of those cells are expressed with both a-SMA and
STAT3, as shown in Figure 3d, we suggest that STAT3 may
also mediate the progression of renal fibrosis through
increasing survival and proliferation of renal interstitial
fibroblasts. Consequently, inhibition of STAT3-mediated
renal interstitial fibroblast proliferation and survival would
be additional mechanisms for alleviating the development of
renal interstitial fibrosis.
In summary, our results clearly show that inhibition of
STAT3 with S3I-201 can suppress activation and prolifera-
tion, and induce death of renal interstitial fibroblasts.
Furthermore, S3I-301 treatment inhibits excessive deposition
of ECM and transcriptional expression of TGF-b1, TbRII,
and several proinflammatory cytokines that are associated
with progressive kidney diseases. Therefore, inhibition of the
STAT3 signaling pathway by S3I-201 may provide a novel
approach to prevent the development of nephropathy and
attenuate the progression of renal fibrosis.
MATERIALS AND METHODS
Chemicals and antibodies
S3I-201 was purchased from Calbiochem (La Jolla, CA, USA).
Antibodies to STAT3, p-STAT1, p-STAT3, p-STAT5, and b-catenin
were purchased from Cell Signaling Technology (Danvers, MA,
USA). Anti-fibronectin was purchased from BD transduction
Laboratory (Lexington, KY, USA). Primers were synthesized from
Invitrogen (Carlsbad, CA, USA). STAT3 siRNA and silencer negative
control siRNA were purchased from Invitrogen. Antibodies to
a-SMA and a-tubulin, the naphthol-AS-D-chloroacetate esterase
kit, and all other chemicals and blocks were obtained from Sigma
(St Louis, MO, USA).
Cell culture and treatments
NRK-49F cells were cultured in Dulbecco’s modified Eagle’s medium
(Sigma-Aldrich) containing 10% fetal bovine serum, 0.5% penicillin
and streptomycin in an atmosphere of 5% CO2 and 95% air at 37 1C.
Transfection of siRNA into cells
The siRNA oligonucleotides targeted specifically to STAT3
(200 pmol) were transfected into NRK-49F cells (1 106) using
the Amaxa Cell Line Nucleofector Kit T (Lonza Cologne AG,
Cologne, Germany) and the Amaxa Nucleofector device according
to the manufacturer’s instructions (Amaxa Biosystem, Gaithersburg,
MD, USA).
Unilateral ureteral obstruction (UUO) model and S3I-201
treatment
The UUO model was established in male C57 black mice that
weighed 20–25 g (Jackson Laboratory, Bar Harbor, ME, USA), as
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Figure 9 | Effect of S3I-201 on infiltration of leukocytes. Kidney
sections were evaluated for infiltration of neutrophils and
monocytes with naphthol-AS-D-chloroacetate esterase staining.
Photomicrographs illustrate infiltration of neutrophils and
monocytes (red color directed by arrows) in different groups: (a)
sham with vehicle; (b) sham with S3I-201; (c) UUO with vehicle;
and (d) UUO with S3I-201. (e) Infiltrated neutrophils and
monocytes were counted in three random fields of each sample,
and 18 fields (1  200) were analyzed for each condition. Data are
mean ± s.e.m. (n¼ 6). Significant P-values reflecting differences
are indicated over the bars (*Po0.05; **Po0.01).
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described previously.47 The contralateral kidneys were used as
controls. To examine the efficacy of S3I-201 in renal fibrosis after
UUO injury, S3I-201 (10mg/kg) in 50 ml of dimethyl sulfoxide was
intraperitoneally administered to mice immediately after ureter
ligation and then given daily for 6 or 13 days. Mice were randomized
into four groups with 6–7 mice in each group as follows: (1) sham
injury with dimethyl sulfoxide as vehicle; (2) sham injury with S3I-
201; (3) UUO injury with dimethyl sulfoxide; and (4) UUO injury
with S3I-201.
Western blot analysis
Immunoblot analysis for NRK-49F cells and tissue samples was
carried out according to our previous protocols.47
Sirius red and immunofluorescent staining
Sirius red and immunofluorescent staining was based on the
procedure described in our previous studies.47
Quantitative real-time PCR
Real-time quantitative reverse transcriptase PCR amplifications were
performed in 20ml reactions (Table 1). The amplification protocol
was as follows: denaturation for 10min and enzyme activation at
95 1C, 40 cycles of 95 1C 10 s, 59 1C 30 s, and 72 1C 20 s,
followed by one-step annealing at 72 1C for 5min. Relative mRNA
abundance was determined from the ratios of specific mRNA to 18S
ribosomal RNA measured in the same samples, and fold change was
calculated relative to the group of sham-operated mice with vehicle
treatment.
ELISA
Protein levels of TGF-b1, TNF-a, and IL-1b in kidney homogenates
were determined using specific sandwich enzyme immunometric
assay kits, ELISA Ready-SET-Go (eBioscience San Diego, CA, USA),
as described previously.48 The results were normalized by total
protein content in kidney homogenates.
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Figure 10 | Effect of S3I-201 on the expression of tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b), monocyte chemotactic
protein-1 (MCP-1), and intercellular adhesion molecule-1 (ICAM-1). mRNA extracted from kidney tissues were subjected to quantitative
real-time reverse transcriptase PCR as described in ‘Materials and Methods’. mRNA expression levels of TNF-a (a), IL-1b (b), MCP-1 (c),
and ICAM-1 (d) were indicated as fold induction over control (sham with vehicle). Protein expression levels of TNF-a (e) and IL-1b (f) in
each group were measured by the enzyme-linked immunosorbent assay (ELISA). Data are means ± s.e.m. (n¼ 6). Significant P-values
reflecting differences are indicated over the bars (*Po0.05; **Po0.01).
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In situ TUNEL assays
The TUNEL staining was used to detect DNA strand breaks using a
detection kit, according to the instructions provided by the
manufacturer. The number of TUNEL-positive nuclei per field was
evaluated in five fields per section and five sections per kidney.
Statistical analysis
All the experiments were conducted at least three times. Data
depicted in graphs represent the mean±s.e.m. for each group.
Multiple means were compared using Tukey’s test. The differences
between two groups were determined by Student’s t-test. Statistical
significant difference between mean values was marked in each
graph. Po0.05 is considered to be significant.
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SUPPLEMENTARY MATERIAL
Figure S1. Effect of STAT3 inhibition on the expression and
phosphorylation of STAT1 and STAT5.
Figure S2. Effect of S3I-201 on the mRNA expression of TGF-b1, TbR1,
TbR II and TbR III in cultured renal interstitial fibroblasts.
Figure S3. Effect of S3I-201 on the phosphorylation of STAT3 and
expression of collagen type I and a-SMA on day 14 after UUO injury.
Figure S4. Effect of S3I-201 on the expression of b-catenin and Snail
on day 7 after UUO injury.
Figure S5. Effect of S3I-201 on apoptosis after UUO injury.
Figure S6. Effect of S3I-201 on proliferation of interstitial cells after
UUO injury.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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